You are here: Industry Insights > Ontruzant

News List

Merck announces US launch of ONTRUZANT, a biosimilar of Herceptin pharmaceutical-business-review
April 20, 2020
Merck announced the US launch of ONTRUZANT (trastuzumab-dttb), as a biosimilar of the reference biologic medicine Herceptin.
Samsung Bioepis, Merck Launch Trastuzumab Biosimilar americanpharmaceuticalreview
April 16, 2020
Samsung Bioepis announced ONTRUZANT® (trastuzumab-dttb), a biosimilar of the reference biologic medicine HERCEPTIN® (trastuzumab) for the treatment of ...
Samsung Bioepis Announces FDA Approval of 420 mg Multi-dose Vial of ONTRUZANT americanpharmaceuticalreview
March 25, 2020
Samsung Bioepis announced the U.S. Food and Drug Administration (FDA) has approved a 420 mg multi-dose vial of ONTRUZANT® (trastuzumab-dttb).
Long-term data shows promise in breast cancer biosimilar pharmatimes
April 03, 2019
The a three-year follow-up study comparing biosimilar Ontruzant (trastuzumab) to a reference version - Herceptin - has found that the drug shows comparable overall survival and cardiac safety in early or locally advanced HER2-positive breast cancer.
Samsung Bioepis secures FDA approval for cancer drug Ontruzant pharmaceutical-technology
January 22, 2019
The US Food and Drug Administration (FDA) has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a range of cancers.....
FDA approves Ontruzant (trastuzumab-dttb), 3rd biosimilar to Herceptin (trastuzumab) firstwordpharma
January 21, 2019
FDA today approved Ontruzant (trastuzumab-dttb), a biosimilar to U.S.-licensed Herceptin (trastuzumab).
Ontruzant launches to become first Herceptin biosimilar available in the UK pharmafile
March 09, 2018
Ontruzant, the biosimilar version of Herceptin originally developed by Korean firm Samsung Bioepis, has launched for patients in the UK